Streetbeat News

Earnings

TARS

Tarsus Pharmaceuticals' stock price has increased following the release of their Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 5:11 pm

ORGO

Organogenesis Holdings' stock is trading higher following the release of their Q3 financial results and the announcement of their revenue guidance for the full year 2023.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 5:10 pm

VIRI

Virios Therapeutics (NASDAQ:VIRI) is expected to release its quarterly earnings report on Monday, 2023-11-13, with an estimated EPS of $-0.09. Investors are looking for an earnings beat and positive guidance for the next quarter. Historically, the company's stock price has been sensitive to earnings performance, with a 20.31% drop after missing EPS last quarter. Shares are currently trading at $0.75, up 190.5% over the last 52 weeks, indicating a bullish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

November 10, 2023 | 5:02 pm

SPRO

Spero Therapeutics (NASDAQ:SPRO) is expected to release its quarterly earnings report on Monday, 2023-11-13, with an estimated EPS of $-0.03. Investors are looking for an earnings beat and positive guidance for the next quarter. Historically, Spero's stock price has reacted negatively to past earnings reports, even with an EPS beat last quarter. Over the last year, SPRO shares have declined by 45.81%, indicating dissatisfaction among long-term shareholders.

Portfolio Pulse from Benzinga Insights

November 10, 2023 | 5:02 pm

EYEN

Eyenovia (NASDAQ:EYEN) is scheduled to release its quarterly earnings report on Monday, 2023-11-13, with analysts expecting an EPS of $-0.17. Investors are looking for an earnings beat and positive guidance for the next quarter. In the past, EPS beats have led to share price increases, such as a 2.46% rise after last quarter's report. However, over the last 52 weeks, EYEN shares have declined by 32.78%, indicating general negative sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

November 10, 2023 | 5:02 pm

AAOI

Applied Optoelectronics' stock is trading lower after the company reported its third-quarter earnings, which likely did not meet investor expectations.

Portfolio Pulse from Benzinga Newsdesk

November 10, 2023 | 5:02 pm

BIOR

Biora Therapeutics (NASDAQ:BIOR) is scheduled to release its quarterly earnings report on Monday, 2023-11-13, with analysts expecting an EPS of $-0.76. Investors are looking for an earnings beat and positive guidance for the next quarter. Biora's past earnings performance shows mixed results with both beats and misses, and varied stock price reactions. Shares are currently trading at $1.49, down 79.94% over the last 52 weeks, indicating a negative sentiment among long-term shareholders ahead of the earnings release.

Portfolio Pulse from Benzinga Insights

November 10, 2023 | 5:02 pm

JRSH

Jerash Holdings (US) (NASDAQ:JRSH) is scheduled to release its quarterly earnings report on Monday, 2023-11-13, with analysts expecting an EPS of $0.07. Investors are looking for an earnings beat and positive guidance for future growth. Historically, the company's stock price has been sensitive to earnings performance and guidance rather than just earnings beats or misses. Last quarter, Jerash Holdings beat EPS estimates but saw a 10.03% drop in share price the following day. Over the last year, the stock has declined by 25.38%.

Portfolio Pulse from Benzinga Insights

November 10, 2023 | 5:02 pm

DMAC

DiaMedica Therapeutics (NASDAQ:DMAC) is expected to release its quarterly earnings report on Monday, 2023-11-13, with analysts predicting an EPS of $-0.13. Investors are looking for an earnings beat and positive guidance for the next quarter. Historically, DMAC's stock price has reacted to both earnings outcomes and guidance. Last quarter, DMAC beat the EPS estimate by $0.02, leading to a 4.4% stock price increase the following day. Over the last year, DMAC shares have risen by 101.7%, trading at $2.35 as of November 09.

Portfolio Pulse from Benzinga Insights

November 10, 2023 | 5:02 pm

ICMB

Investcorp Credit (NASDAQ:ICMB) is scheduled to release its quarterly earnings report on Monday, 2023-11-13, with analysts expecting an EPS of $0.14. Investors are looking for an earnings beat and positive guidance for the next quarter. Historically, ICMB's stock price has been sensitive to earnings performance and guidance. Last quarter, the company missed EPS estimates by $0.02, resulting in a 6.02% share price drop the following day. Over the last year, ICMB shares have declined by 8.47%, trading at $3.37 as of November 09.

Portfolio Pulse from Benzinga Insights

November 10, 2023 | 5:02 pm